

In one aspect, there is provided the compound (S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone in crystalline form; characterized by: the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction  $2\theta$ : 8.6°, 15.2°, and 21.3°; or the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction  $2\theta$ : 13.4°, 18.3°, and 24.0 wherein said X-ray powder diffraction diagram is obtained by using combined Cu  $K\alpha_1$  and  $K\alpha_2$  radiation, without  $K\alpha_2$  stripping; and the accuracy of the  $2\theta$  values is in the range of  $2\theta \pm 0.2^\circ$ .

Another aspect relates to the compound as disclosed herein, for use as a medicament

Another aspect relates to a pharmaceutical composition comprising as active ingredient the compound as disclosed herein and at least one pharmaceutically acceptable carrier

Another aspect relates to the use of the compound as disclosed herein for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, and appetite disorders.

Another aspect relates to the use of the compound or a pharmaceutical composition as disclosed herein in the manufacture of a medicament for the treatment or prevention of sleep disorders selected from the group consisting of dyssomnias and parasomnias.

## Claims

1. The compound (S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone in crystalline form; characterized by:

- 5       • the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction  $2\theta$ :  $8.6^\circ$ ,  $15.2^\circ$ , and  $21.3^\circ$ ; or
- the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction  $2\theta$ :  $13.4^\circ$ ,  $18.3^\circ$ , and  $24.0^\circ$ ;

      wherein said X-ray powder diffraction diagram is obtained by using combined Cu  $K\alpha_1$  and  $K\alpha_2$  radiation, without  $K\alpha_2$  stripping; and the accuracy of the  $2\theta$  values is in the range of  $2\theta \pm 0.2^\circ$ .

10

2. The compound according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction  $2\theta$ :  $8.6^\circ$ ,  $15.2^\circ$ , and  $21.3^\circ$ ; wherein said X-ray powder diffraction diagram is obtained by using combined Cu  $K\alpha_1$  and  $K\alpha_2$  radiation, without  $K\alpha_2$  stripping; and the accuracy of the  $2\theta$  values is in the range of  $2\theta \pm 0.2^\circ$ .

15

3. The compound according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction  $2\theta$ :  $8.6^\circ$ ,  $11.5^\circ$ ,  $13.4^\circ$ ,  $14.6^\circ$ ,  $15.2^\circ$ ,  $15.5^\circ$ ,  $19.3^\circ$ ,  $21.3^\circ$ ,  $22.4^\circ$ , and  $26.4^\circ$ ; wherein said X-ray powder diffraction diagram is obtained by using combined Cu  $K\alpha_1$  and  $K\alpha_2$  radiation, without  $K\alpha_2$  stripping; and the accuracy of the  $2\theta$  values is in the range of  $2\theta \pm 0.2^\circ$ .

20

4. The compound according to claims 2 or 3, which essentially shows the X-ray powder diffraction pattern as depicted in Figure 2.

5. The compound according to any one of claims 2 to 4, wherein said crystalline form is a hemi-hydrate.

25

6. The compound according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction  $2\theta$ :  $13.4^\circ$ ,  $18.3^\circ$ , and  $24.0^\circ$ ; wherein said X-ray powder diffraction diagram is obtained by using combined Cu  $K\alpha_1$  and  $K\alpha_2$  radiation, without  $K\alpha_2$  stripping; and the accuracy of the  $2\theta$  values is in the range of  $2\theta \pm 0.2^\circ$ .

7. The compound according to claim 1, characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction  $2\theta$ :  $10.9^\circ$ ,  $13.4^\circ$ ,  $14.3^\circ$ ,  $14.9^\circ$ ,  $18.3^\circ$ ,  $20.9^\circ$ ,  $21.1^\circ$ ,  $21.8^\circ$ ,  $24.0^\circ$ , and  $30.1^\circ$ ; wherein said X-ray powder diffraction diagram is obtained by using combined Cu  $K\alpha_1$  and  $K\alpha_2$  radiation, without  $K\alpha_2$  stripping; and the accuracy of the  $2\theta$  values is in the range of  $2\theta \pm 0.2^\circ$ .

8. The compound according to claims 7 or 8, which essentially shows the X-ray powder diffraction pattern as depicted in Figure 3.

9. The compound according to any one of claims 6 to 8, wherein said crystalline form is an anhydrate.

10. The compound according to any one of claims 1 to 9, for use as a medicament.

20

25

30

11. A pharmaceutical composition comprising as active ingredient the compound according to any one of claims 1 to 9, and at least one pharmaceutically acceptable carrier.

12. The compound according to any one of claims 1 to 9, or a pharmaceutical composition according to claim 11 for use in the treatment or prevention of a disease or disorder selected from the group consisting of sleep disorders selected from the group consisting of dyssomnias and parasomnias; anxiety disorders; and addiction disorders.

13. Use of the compound according to any one of claims 1 to 9 for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, and appetite disorders.

14. Use of the compound according to any one of claims 1 to 9, or a pharmaceutical composition according to claim 11 in the manufacture of a medicament for the treatment or prevention of sleep disorders selected from the group consisting of dyssomnias and parasomnias.